« Return to News | R&D Trends

Pfizer and Hisun to increase access to high-quality generics

Wednesday, February 22, 2012 02:00 PM

Pfizer and Zhejiang Hisun Pharmaceutical are establishing a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

The agreement builds on the companies’ memorandum of understanding (MOU) and aims to strengthen the ability of both companies to reach more patients with high-quality medicines in the branded generics arena.

The potential joint venture will be named Hisun Pfizer Pharmaceutical Co. Hisun will own 51% and Pfizer will own 49%, and the aggregate investment and registered capital will be $295 million and $250 million, respectively. Both parties could contribute selected existing products, manufacturing sites, cash and other relevant assets after the joint venture is formed.

The potential joint venture is subject to the satisfaction of certain closing conditions, including approval of relevant government authorities in China.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.